Три регол

Quick links to important sections

Три регол

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Три регол

Property Description
Active Ingredients Ethinyl Estradiol, Levonorgestrel
Form Coated Tablets (Triphasic Preparation)
Pharmacological Class Hormonal Contraceptives for Systemic Use (ATC G03AB03)
Common Use Systemic Contraception (Pregnancy Prevention)
Origin Synthetic Hormones

What Type of Contraceptive is Три регол?

Три регол (Tri-Regol) is a prescription-only combined oral contraceptive (COC), a preparation containing two types of synthetic sex hormones and administered via the oral route in the form of coated tablets. It is manufactured by Gedeon Richter. It is classified under the high-level pharmacological class of hormonal contraceptives for systemic use, specifically designated as a sequential preparation of progestogens and estrogens within the Anatomical Therapeutic Chemical (ATC) classification system under code G03AB03.

This preparation is structurally identified as a triphasic system, a feature clinically recognized for its attempt to mimic the natural hormone rhythm of the female cycle by varying the concentrations of its active ingredients across the 21-day regimen. This design differentiates it from monophasic products and offers a specific structural type of systemic contraception.


Ethinyl Estradiol and Levonorgestrel: Composition and Origin

The composition of Три регол relies on two key synthetic hormones that act as the active ingredients: Ethinyl Estradiol, the estrogen component, and Levonorgestrel, the progestogen component. These compounds are steroid derivatives, confirming their synthetic origin rather than extraction from natural sources. As a combination drug, the therapeutic function is derived from the controlled systemic delivery of both hormones, which provides effective contraception for women of reproductive potential.


What is the Main Purpose of Три регол?

The overriding purpose of Три регол is the achievement of reliable systemic contraception, which is the highly effective prevention of pregnancy. This goal is achieved through coordinated physiological actions driven by the synthetic hormones. The primary action involves the inhibition of ovulation, where the hormones suppress the endocrine signals necessary for the monthly release of an egg. Additionally, the drug alters the physical environment of the reproductive tract, including increasing the viscosity of the cervical mucus and modifying the uterine lining. These combined effects establish a predictable and reversible method of pregnancy prevention.

Regulatory References

  1. Ethinyl Estradiol and Levonorgestrel (Oral Contraceptives): MedlinePlus Drug Information

What side effects are possible with Три регол?

Possible Side Effects and Safety Information

Tri-Regol (a combination of ethinyl estradiol and levonorgestrel) is a prescription medication, and like all medications, it may cause side effects, though not everyone experiences them. Side effects are often temporary, especially during the first few cycles as the body adjusts to the hormones.

Common Side Effects

Commonly reported side effects can include:

  • Gastrointestinal: Nausea, vomiting, and abdominal pain.
  • Hormonal: Breast tenderness or pain, breakthrough bleeding or spotting between periods, and changes in menstrual flow.
  • Other: Headaches, weight gain, and mood changes (including depression or nervousness).

Serious Risks and Warning Signs

All combined hormonal contraceptives carry a slightly increased risk of serious, though rare, side effects. It is vital to seek immediate medical attention if you experience any signs of the following conditions:

Condition Warning Signs to Report Immediately
Blood Clots (Thrombosis) Sudden severe pain or swelling in the leg, sharp chest pain, sudden shortness of breath, sudden changes in vision.
Stroke or Heart Attack Sudden severe headache, slurred speech, sudden weakness or numbness on one side of the body, chest pain.
Liver Problems Severe abdominal pain, yellowing of the skin or eyes (jaundice), dark urine, or pale stools.
Severe Allergic Reaction Swelling of the face, lips, tongue, or throat, or difficulty breathing.

Contraindications and Safety

Tri-Regol is not suitable for everyone. Do not take this medication if you have a history of blood clots, certain heart conditions, severe high blood pressure, migraines with aura, breast or other hormone-sensitive cancers, or unconfirmed abnormal vaginal bleeding. Smoking significantly increases the risk of serious cardiovascular side effects, particularly in women over the age of 35. This medication does not protect against sexually transmitted infections (STIs), including HIV/AIDS.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Три регол

Overdose Scope Documented overdose presentations of Ethinyl Estradiol and Levonorgestrel combination products primarily affect the gastrointestinal, reproductive, and central nervous systems. Symptoms recorded in official labeling for acute excess ingestion include nausea, vomiting, headache, drowsiness, and breast tenderness. A common reproductive sign is the occurrence of vaginal bleeding, which typically manifests as a withdrawal bleed expected several days after the acute exposure. No unique manifestations or immediate actions are explicitly documented for specific populations.

Overdose Classifications (High-Level) Regulatory documents classify the acute overdose as not likely to be life-threatening. Emergency-response statements mandate that individuals seek medical help right away and contact a regional Poison Control Centre if any suspected overdose occurs. No specific antidote is known for this combination, and treatment is symptomatic and supportive.

Official Overdose Statements:

  • Overdose primarily presents with non-life-threatening hormonal effects, including nausea, vomiting, and subsequent vaginal bleeding.
  • Official guidance mandates that individuals seek medical help right away and contact a regional Poison Control Centre.
  • There is no specific antidote known for this overdose, and care is symptomatic and supportive.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by its acute, non-lethal nature and expected hormonal manifestations. This framework mandates that, despite the low acute risk, immediate medical contact is required for professional assessment, supportive management, and adherence to specific regulatory follow-up protocols, such as required liver enzyme monitoring (transaminase levels) two to three weeks post-ingestion.

Therapeutic Uses of Три регол

What Три регол Treats: Main Uses and Benefits

Три регол is commonly used for systemic contraception, which is considered relevant for pregnancy prevention in women of reproductive potential. The medication is also applied across therapeutic domains where additional symptomatic support is needed.

Therapeutic Support and Comfort

The primary use is pregnancy prevention. Additionally, the medication is relevant for easing symptoms associated with menstrual cycle irregularity, painful periods (dysmenorrhea), excessive menstrual blood loss, and hormone-related acne.

This medication is commonly applied in clinical settings to support a more predictable menstrual pattern for women experiencing irregularity. It is applied in addressing the symptom burden associated with cyclical discomfort, which generally contributes to improved comfort and may assist with maintaining functional stability.

It helps manage the distressing manifestations of Premenstrual Syndrome (PMS), offering supportive relief that allows patients to cope more steadily with these episodes. The overall therapeutic role is to contribute to improved day-to-day comfort and stability during symptomatic periods.


Quick Fact: Supportive Management for Cyclical Discomfort

Regulatory References

  1. NIH MedlinePlus overview of oral contraceptives

Eligibility and Restrictions for Use

Official Eligibility: Who Can and Cannot Use Tri-Regol

Eligibility to use Tri-Regol (Levonorgestrel and Ethinyl Estradiol) is strictly defined by regulatory guidelines, focusing on absolute exclusions related to vascular, hormonal, and hepatic risk.

Contraindicated Populations and Conditions

Use is absolutely prohibited (contraindicated) for individuals with a history of or current serious health issues, including:

  • Thromboembolic Risk: A history of or current venous or arterial thromboembolic events (e.g., DVT, PE, stroke, heart attack).
  • Smoking and Age: Women over 35 who smoke are strictly forbidden from using this medicine due to significantly elevated cardiovascular risk.
  • Malignancy: Known or suspected sex hormone-dependent cancers (e.g., breast cancer).
  • Hepatic Issues: Severe liver disease, liver tumors (benign or malignant), or liver function that has not returned to normal.
  • Other: Migraine with focal neurological symptoms (aura), severe uncontrolled hypertension, and diabetes with vascular involvement.

Use Restrictions and Special Status

  • Pregnancy and Lactation: Tri-Regol is contraindicated in pregnancy and must be stopped immediately if pregnancy occurs. Use is not recommended during breastfeeding as it may reduce milk quality and quantity.
  • Surgery/Immobilization: The medicine must be temporarily stopped, typically four weeks prior to major surgery or during prolonged immobilization, due to the increased risk of blood clots.

Eligibility is limited to adult women of childbearing potential and adolescents after menarche, provided none of the contraindications are present.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for combined oral contraceptives like Три регол identifies specific interaction patterns that can alter hormone exposure or enhance known risks.


Formal Restrictions and Co-Administration Rules

Classification Constraint Context
Contraindicated Combination Must not be co-administered with Hepatitis C drug combinations containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir Documented risk of liver enzyme (ALT) elevations.
Substance Contraindication Contraindicated in women over age 35 who smoke Significantly increased risk of serious cardiovascular events.
Timing Requirement Oral contraceptives should be administered at least 4 hours before Colesevelam To ensure adequate absorption of the active ingredients.

Pharmacokinetic and Pharmacodynamic Interactions

Interactions are primarily based on the drug's metabolism. Hepatic enzyme inducers (e.g., certain anticonvulsants or the herbal product St. John's wort) are known to increase the clearance of the hormones, potentially leading to a decrease in effectiveness. Conversely, strong CYP inhibitors may increase plasma concentrations of Ethinyl Estradiol, a change theoretically associated with an increased risk of thrombosis. Furthermore, pharmacodynamic antagonism is documented with certain drugs; for example, the estrogen component may decrease the effect of Anastrozole. The estrogen component may also increase the serum concentrations of other co-administered substances, such as systemic corticosteroids, by raising the level of specific binding globulins.

Mechanism of Action

The mechanism of Три регол (Ethinyl Estradiol and Levonorgestrel) is defined by three overlapping, coordinated physiological actions on the reproductive system.

Central Suppression of the Neuroendocrine Control System

The drug's primary mechanism involves the synthetic hormones acting as agonists at Estrogen Receptors (ER) and Progesterone Receptors (PR) in the hypothalamus and pituitary gland. This sustained receptor activation exerts continuous negative feedback on the Hypothalamic-Pituitary-Ovarian (HPO) Axis, leading to the suppression of FSH and the critical LH surge. This central molecular cascade results in the primary physiological effect of sustained anovulation, preventing the release of an egg from the ovary.

Modulation of Peripheral Tissue Barriers

The Levonorgestrel component directly modulates the secretory glands of the cervix. This local action alters the physicochemical properties of the cervical mucus, causing a significant increase in viscosity and thickness. This physiological change creates a dense physical barrier that impedes the movement of sperm into the upper reproductive tract.

Alteration of Endometrial Receptivity

The combination of synthetic hormones also influences the development and maturation of the endometrium (uterine lining). The resulting altered, unreceptive endometrial state contributes to the prevention of implantation in the event of a primary mechanism failure and subsequent fertilization. This secondary physiological barrier supports the overall physiological effect by providing a distinct, secondary line of physiological action.

Dosage and Administration Information

How to use Три регол — Official Administration Guidelines

Три регол (Levonorgestrel/Ethinyl Estradiol) is administered orally and must be taken daily according to a strict 21-day/7-day cyclical schedule. To ensure consistency, the tablet should be ingested at approximately the same time each day, regardless of meals.

Dosing Schedule

One tablet is taken daily for 21 consecutive days, followed by a 7-day tablet-free interval. A new pack must be started on the day immediately following the 7-day break, irrespective of whether the withdrawal bleed has ceased. The tablet types must be taken in the sequential order indicated on the blister pack:

  • Day 1–6: One yellow tablet daily.
  • Day 7–11: One light beige tablet daily.
  • Day 12–21: One white tablet daily.

Starting use requires the first tablet to be taken on the first day of the natural menstrual cycle (the first day of bleeding). If started on days 2–5, an additional non-hormonal method of contraception is advised for the first seven days of the first cycle.

Missed Dose Instructions

Missed Dose Timing Action Protocol
Less than 12 hours late Take the missed tablet immediately. Contraceptive protection is maintained. Continue subsequent tablets at the usual time.
More than 12 hours late Take the last missed tablet immediately. Continue remaining tablets at the usual time (even if two tablets are taken on the same day).
More than 12 hours late, Week 1 Take the missed tablet. Use additional non-hormonal contraception (e.g., barrier method) for the next 7 days. Pregnancy possibility should be considered if intercourse occurred in the preceding week.
More than 12 hours late, Week 3 Option 1: Take the missed tablet and start the next pack immediately after finishing the current pack (skipping the 7-day interval). Option 2: Stop the current pack, observe a 7-day break (including the missed dose day), and then start a new pack. In both options, additional non-hormonal contraception is advised for the next 7 days.

Recent Clinical Evidence

Recent Clinical Evidence

Tri-Regol is a triphasic combined oral contraceptive (COC) containing the estrogen ethinylestradiol (EE) and the progestogen levonorgestrel (LNG). As a second-generation triphasic pill, its use in clinical practice is often evaluated in comparison to monophasic and newer-generation COCs, focusing on efficacy, cycle control, and safety profiles.

Contraceptive Efficacy and Cycle Control

Clinical trials examining levonorgestrel/ethinylestradiol combinations have demonstrated high contraceptive reliability. Research specifically on Tri-Regol and similar triphasic formulations has focused heavily on bleeding patterns and tolerability.

  • Bleeding Patterns: Some comparative studies have shown that triphasic formulations, including those with levonorgestrel, may offer improved stability and cycle control, particularly in terms of reducing the incidence of intermenstrual bleeding or spotting, compared to some fixed-dose monophasic preparations. Failure of expected withdrawal bleeding has been reported as rare across most formulations, including the triphasic type.

Safety Profile and Non-Contraceptive Benefits

General epidemiological evidence on COCs is highly relevant to this formulation. The progestogen levonorgestrel is classified as a second-generation progestogen. Research suggests that second-generation pills may carry a slightly lower risk of venous thromboembolism (VTE) compared to some third-generation pills (those containing gestodene or desogestrel). However, the absolute increased risk remains small compared to the risk associated with pregnancy.

Non-contraceptive effects commonly associated with combined hormonal contraceptives, such as the potential for improved acne and regulation of the menstrual cycle, have also been reported in studies involving levonorgestrel/ethinylestradiol formulations.

Assessment Area Reported Study Findings
Hormonal Profile Levonorgestrel at contraceptive doses is associated with a non-androgenic clinical profile, including increased sex hormone-binding globulin (SHBG) levels.
Restoration of Fertility Studies have noted the quick restoration of ovulation (usually within three months) following the discontinuation of the preparation.

Key Studies & References

  1. Combined Hormonal Contraception: ACOG Practice Bulletin, Number 206
  2. Combined oral contraceptives for treatment of acne and hirsutism: a systematic review

Frequently Asked Questions (FAQ)

Common questions about Три регол (FAQ)

Q: How quickly does Три регол start working to prevent pregnancy?

A: According to the official product information, if you begin taking the pill on the very first day of your natural menstrual cycle, contraceptive effectiveness may be considered to begin promptly. If the medication is started on Days 2 through 5 of your cycle, an additional non-hormonal method of contraception, like a barrier method, is required for the first seven days of tablet intake to help ensure efficacy.

Q: What is the difference between Три регол and other combined oral contraceptives?

A: Official information confirms that Три регол is a triphasic combined oral contraceptive. This means the dose of the active hormones changes three times throughout the 21-day cycle. This differs from a monophasic pill, where the dose of both hormones remains constant for all 21 active tablets.

Q: Can women over 35 safely use Три регол?

A: Regulatory documents state that this medication is strictly contraindicated (absolutely forbidden) for women over the age of 35 who smoke, due to a significantly increased risk of serious cardiovascular complications. For non-smoking women over 35, a healthcare provider determines eligibility based on an individual risk assessment.

Q: Can I switch directly from another birth control pill to Три регол?

A: Official administration guidelines provide specific directions for switching between brands. Typically, the first tablet of Три регол is started on the day following the last active hormone tablet from your previous pill pack, meaning the hormone-free interval or placebo week of the old pill is skipped.

Q: What are the signs of a serious, but rare, side effect from Три регол?

A: The presence of warning signs requires immediate medical attention and should be reported promptly to a healthcare provider. Serious warning signs include sudden, severe pain or swelling in the leg (potential blood clot), sharp chest pain, sudden shortness of breath, or a sudden, severe headache. Jaundice (yellowing of the skin or eyes) is also a sign to report.

Q: How long does it take for fertility to return after stopping Три регол?

A: Official studies and information indicate that the return of ovulation typically occurs within three months following discontinuation of the medication. This is based on examining the hormonal profile after stopping the preparation.

Q: Is it safe to use Три регол if I'm planning to get pregnant soon after stopping?

A: This medication is contraindicated (not allowed) during pregnancy and should be stopped immediately if pregnancy is confirmed. However, studies show ovulation often returns quickly after discontinuation, meaning there is no evidence to suggest that its use causes a prolonged delay in the return of fertility.

Q: What is the expected timeline for side effects to subside after starting Три регол?

A: According to official product information, common side effects are often temporary. Most women experience an adjustment period during the first few cycles as their body adapts to the synthetic hormones, after which side effects typically subside.

Q: Does Три регол cause weight gain or changes in appetite?

A: Official regulatory labels for combined oral contraceptives containing these hormones list increased weight as a commonly reported adverse reaction. Changes in appetite are not typically specified in the core product information.

Q: Can Три регол affect mood or cause emotional changes?

A: Yes, official safety information indicates that mood changes are listed as commonly reported side effects. These emotional changes can include feelings of depression or nervousness.

Q: Is it normal to have lighter or shorter periods on Три регол?

A: Official information lists changes in menstrual flow as a common side effect of the pill. The hormonal combination frequently results in a lighter, shorter, and often more predictable withdrawal bleed compared to a natural menstrual period.

Q: Can Три регол be prescribed for regulating irregular periods?

A: The primary and officially approved purpose for this medication is to provide highly effective systemic contraception (pregnancy prevention). While the regulation of the menstrual cycle is a recognized non-contraceptive effect, it is not listed as the sole official indication in regulatory documents.

Q: Is it possible to feel dizzy when first taking Три регол?

A: Official post-marketing data for this medication has included reports of dizziness as a possible adverse reaction. If dizziness occurs or is persistent, a healthcare provider should be informed.

Q: Is it normal to miss a period sometimes while taking the active pills of Три регол?

A: Official warnings state that the failure of expected withdrawal bleeding is rare. If a withdrawal bleed does not occur, especially if tablets were missed during the cycle, the possibility of pregnancy needs to be evaluated by a healthcare professional.

Q: Does Три регол affect the results of blood tests?

A: Regulatory labels caution that combined oral contraceptives are known to affect the results of certain laboratory blood tests. Patients taking this medication are generally advised to inform their healthcare provider before having laboratory work performed.

Q: Can taking antibiotics reduce the effectiveness of Три регол?

A: Regulatory information warns that certain enzyme-inducing drugs can decrease the effectiveness of the pill by increasing hormone clearance. Although not all antibiotics are listed as enzyme inducers, caution is advised. For this reason, all medications, including antibiotics, should be discussed with a prescriber.

Q: Can taking certain herbal supplements interfere with Три регол?

A: Yes, regulatory documents explicitly warn against taking the herbal product St. John's wort while using this medication. St. John's wort is known to act as a hepatic enzyme inducer, which can significantly reduce the level of the contraceptive hormones in the blood, potentially decreasing the pill's effectiveness.

How should Три регол be stored and disposed of?

How to Store and Dispose of Три регол?

Regulatory agencies define specific conditions for storing and disposing of Три регол (Ethinyl Estradiol/Levonorgestrel) to maintain product stability and ensure environmental safety.


Official Storage Constraints

Requirement Official Regulatory Mandate
Temperature Store below 25°C and protect from excess heat and moisture.
Packaging Must be kept in the original package (blister/carton) and protected from direct light.
Stability Do not use the tablets after the expiry date printed on the carton.
Child Safety Keep this medicine out of the sight and reach of children.

Disposal Protocol

The official instruction strictly prohibits disposing of unused or expired tablets via wastewater or household waste. These measures are in place to protect the environment. Patients must be directed to ask a pharmacist for the proper method to discard the medicine, ensuring it enters the controlled pharmaceutical waste channel.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Три регол found in:

A-Z Index: